BioCryst Pharmaceuticals Announces Changes to Board of Directors

Dr. Jensen has over 24 years of global drug development experience in both pharmaceutical and biotechnology companies and has been responsible for more than forty new drug approvals in the U.S., Europe and Japan during his career. He most recently served as Corporate Senior Vice President and General Manager, Research & Development (R&D) for Japan and Asia/Pacific at Schering-Plough Corporation, and earlier he held a number of global senior R&D positions at Schering-Plough, including Senior Vice President of Clinical Research. Dr. Jensen previously held senior R&D positions at Chiron and Ciba-Geigy, and a number of academic posts. Dr. Jensen received his M.D. from the University of Copenhagen, where he also completed his post graduate medical training in neurology and internal medicine. Dr Jensen is also a member of the Board of Acorda Therapeutics, Inc.

“I look forward to working with my fellow board members and the leadership team at BioCryst to pursue our goal of building an enduring, successful biopharmaceutical company, addressing patients’ unmet medical needs,” said Dr. Jensen.

“Dr. Jensen shares BioCryst’s passion for serving the needs of patients and healthcare providers. The wealth of experience Peder possesses in a wide range of therapeutic areas is going to be a great asset to BioCryst and its leadership," said Zola P. Horovitz, Ph.D., Chairman of the Board of BioCryst. “Dr. Seidenberg has made invaluable contributions in the strategic development of BioCryst since joining its Board in late 2005. Beth’s dedicated service and firm belief in the company’s long-term potential helped attract proven leaders to BioCryst, and we wish her continued success.”